RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > RAPS News: FDA/EMEA Common Application for Orphan Medicinal Products

RAPS News: FDA/EMEA Common Application for Orphan Medicinal Products

Posted 01 February 2008 | By

On 8 November 2007, the US Food and Drug Administration (FDA) and European Medicines Agency (EMEA) announced a Common Application for Orphan Medicinal Product Designation. The intent of the common application is to reduce the administrative burden on companies who wish to apply to orphan medicinal product designation in both the US and EU and thus, hopefully, to increase the number of products available to treat rare or "orphan" diseases in both jurisdictions.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.